Stroke patients appear to receive better care at teaching hospitals with less of a chance of landing back in a hospital during the early stages of recovery, according to new research from The University of Texas Health Science Center at Houston (UTHealth).
Faculty at The University of Texas Health Science Center at Houston (UTHealth) discuss the diagnosis and treatment of scleroderma, an autoimmune disease affecting an estimated 300,000 people in the United States.
Faculty at The University of Texas Health Science Center at Houston (UTHealth) address the diagnosis and treatment of glaucoma, a leading cause of blindness.
Four years after their publication by the Office of the National Coordinator for Health Information Technology (ONC), voluntary guidelines designed to increase the safety of e-health records have yet to be implemented fully, according to a survey led by a researcher at The University of Texas Health Science Center at Houston (UTHealth). Findings appeared recently in the Journal of the American Medical Informatics Association.
Faculty at The University of Texas Health Science Center at Houston (UTHealth) share tips on how to reduce your risk of a heat-related illness.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Scientists at The University of Texas Health Science Center at Houston (UTHealth) have identified the brain networks that allow you to think of an object name and then verbalize that thought. The study appeared in the July issue of BRAIN. It represents a significant advance in the understanding of how the brain connects meaning to words and will help the planning of brain surgeries.
When it comes to shedding pounds, it pays to think big, according to new research by The University of Texas Health Science Center at Houston (UTHealth).
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, today announced the launch of Magnolia Neurosciences Corporation, a company developing a new class of neuroprotective medicines, with $31 million in Series A funding. The company will develop novel therapeutics based on discoveries made by researchers in MD Anderson’s Therapeutics Discovery division, including the Institute for Applied Cancer Science (IACS) and the Neurodegeneration Consortium (NDC).
For many, just the idea of losing weight can be discouraging. With the endless advice and trends that exist today, configuring a nutritious diet to lose weight and maintain it can be challenging.
When it comes to diet in the Western world of overconsumption where cheap convenience food rules, the age-old adage “everything in moderation” has been put to the test, prompting the American Heart Association (AHA) to issue a science advisory led by researchers at The University of Texas Health Science Center at Houston (UTHealth).
This new facility in the Texas Medical Center will give cardiovascular surgeons, cardiologists, neurosurgeons and neurologists advanced technology that they believe will transform clinical care for the future and will serve as the new standard for similar facilities around the country.
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.
Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology.
Heart transplant patient who had to be hooked up to machines to walk his daughter down the aisle will compete in Olympic-style sporting events at this year's Transplant Games of America.
If you’re the parent of a child with a significant health issue, this time of year means more than just shopping for a colorful new backpack. The safety and success of your child at school is the result of your careful planning and forming partnerships with your child’s school and health care professionals.
Deciding what to give your children to eat and drink is a minefield these days, even when it comes to milk. Once almost universally regarded as a daily dietary staple packed with vitamins and minerals essential for good health, its relationship with consumers over the years has somewhat soured.
Every parent wants their child to feel comfortable in their own skin, but this can seem impossible if that child is afflicted with bad acne or constantly itching from eczema. Such conditions take a terrible toll, as Adelaide Hebert, M.D., professor and director of pediatric dermatology at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), knows only too well.
Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer that has spread to the bone in mice so they can better understand and develop treatment for bone metastasis in humans.
To get your young scholar off to a good start this school year, it’s important to make sure he or she is well-rested when the bell sounds, according to Reeba Mathew, M.D., a sleep expert with McGovern Medical School at The University of Texas of Health Science Center at Houston (UTHealth).
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology. “This simple blood test demonstrates the potential of biomarker-based risk assessment to improve eligibility criteria for lung cancer screening with low-dose computed tomography,” said study co-senior author Sam Hanash, M.D., Ph.D., professor of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center.
The operating rooms where Dr. Michael E. DeBakey and others performed the firsts in the heart surgery will close as the Houston Methodist DeBakey Heart & Vascular Center moves to a new high-tech building.
Enjoying full-fat milk, yogurt, cheese and butter is unlikely to send people to an early grave, according to new research by The University of Texas Health Science Center at Houston (UTHealth).
Richard Pollitt was at the end of his rope after years of suffering regular seizures, with some lasting five minutes and preventing him from working and enjoying his favorite pastimes. Desperate for relief after medications did not work, Pollitt had a small battery-powered device implanted in his skull to control seizures. Now he rarely has them.
Millennials living more dangerously and settling down later could be creating a new generation of addicted smokers and e-cigarette users, according to the surprising results of research by The University of Texas Health Science Center at Houston (UTHealth).
Beginning July 1, James M. Musser, M.D., Ph.D., becomes the 2018-2019 president of the Federation of American Societies for Experimental Biology (FASEB).
A guide to help battle a potentially fatal disease transferred by a blood-sucking insect called the kissing bug has been published by a task force led by The University of Texas Health Science Center at Houston (UTHealth).
A Houston Methodist program that provides specialty patient care to uninsured and underserved patients received another multi-million dollar gift from Occidental Petroleum Corporation.
The American Cancer Society's recent recommendations for changing the colorectal cancer screening age to 45 from age 50 had significant meaning for a Magnolia, Texas woman.
Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center, will share the 2018 Tang Prize in Biopharmaceutical Science for his leadership in developing antibodies to block cancer-promoting growth factor receptors on the surface of cancer cells.
A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML) linked to a genetic mutation called FMS-like internal tandem duplications (FLT3-ITD).
Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers at The University of Texas MD Anderson Cancer Center report today in the Journal of Clinical Investigation.
Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. Their preclinical research was reported in the Journal of the National Cancer Institute.
In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients – those whose tumors expressed SLFN11— who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the PARP-inhibitor sensitivity in SCLC.
A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits a vital metabolic process required for cancer cells’ growth and survival.
When budding doctor Rebecca Thompson graduated from McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) May 18, she furthered a four-generation-strong family legacy.
The University of Texas MD Anderson Cancer Center has named eight researchers to the third annual class of Andrew Sabin Family Fellows. As part of the Andrew Sabin Family Fellowship Program, each researcher will receive $100,000 in funding over two years. The Andrew Sabin Family Foundation established the program through a $30 million endowment to encourage creativity, innovation and highly impactful cancer research in four categories: basic science, clinical, physician-scientist, and population and quantitative science.
Recognizing that vaccination rates for the human papillomavirus (HPV) remain low across the U.S., particularly in Texas, The University of Texas MD Anderson Cancer Center again has joined with the 69 other National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement to call for increased HPV vaccination and evidence-based screening, with the goal of eliminating cancers caused by the virus.
The Houston Advanced Research Center (HARC) in The Woodlands, Texas has been awarded funding from the U.S. Department of Energy (DOE) to assist public and private entities considering Combined Heat and Power (CHP).
The UTHealth High Risk Children’s Program, a collaboration between The University of Texas Health Science Center at Houston (UTHealth) and Children’s Memorial Hermann Hospital, has been named to the national network for Children and Youth Special Health Care Needs (CYSHCN).
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of a common skin cancer, an international team led by a researcher at The University of Texas MD Anderson Cancer Center reports in the New England Journal of Medicine.
In an international Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral FGFR inhibitor erdafitinib (ERDA) was well-tolerated and achieved a robust response for patients with metastatic urothelial, or urinary tract, cancers harboring mutations in the FGFR3 gene.
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease.
Matching targeted therapies to tumor-specific gene mutations across tumor types improved progression-free survival (PFS) and overall survival (OS) in patients with advanced disease relative to those receiving non-matched treatment (NMT), according to research from The University of Texas MD Anderson Cancer Center. The researchers also found that receiving matched targeted therapy (MTT) was an independent factor for predicting longer OS.
In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time of surgery. If further validated in larger, confirmatory trials, the oral medication could replace chemotherapy for these patients.
The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen’s early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.
The WorldFest-Houston International Film Festival has honored a 56-minute film produced by Cizik School of Nursing at The University of Texas Health Science Center at Houston (UTHealth) with a Platinum Remi Award given for a documentary under 60 minutes. The original documentary film, Caring Corrupted: the Killing Nurses of the Third Reich, is a grim cautionary story about nurses who participated in the Holocaust and abandoned their professional ethics during the Nazi era.
When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSAID), they increased its anticancer properties and reduced its side effects. Findings of the preclinical study of phosphatidylcholine, also called lecithin, appear in the journal Oncology Letters.
Betty Ozen has a spring in her step again, thanks to her quick-acting daughter, the wonders of telemedicine and a helping paw from Jojo.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right